Last update 20 Mar 2025

Pamiparib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PARPi, PARPi - BeiGene, PARTRUVIX
+ [5]
Action
inhibitors
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationConditional marketing approval (China), Special Review Project (China), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC16H15FN4O
InChIKeyDENYZIUJOTUUNY-MRXNPFEDSA-N
CAS Registry1446261-44-4

External Link

KEGGWikiATCDrug Bank
D11426-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
BRCA-mutated Fallopian Tube Carcinoma
China
30 Apr 2021
BRCA-mutated Fallopian Tube Carcinoma
China
30 Apr 2021
BRCA-mutated Ovarian Cancer
China
30 Apr 2021
BRCA-mutated Ovarian Cancer
China
30 Apr 2021
BRCA-mutated Peritoneal Neoplasms
China
30 Apr 2021
BRCA-mutated Peritoneal Neoplasms
China
30 Apr 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 3
Italy
19 Dec 2019
Advanced cancerPhase 3
Taiwan Province
19 Dec 2019
Advanced cancerPhase 3
New Zealand
19 Dec 2019
Advanced cancerPhase 3
United States
19 Dec 2019
Advanced cancerPhase 3
Japan
19 Dec 2019
Advanced cancerPhase 3
Poland
19 Dec 2019
Advanced cancerPhase 3
France
19 Dec 2019
Advanced cancerPhase 3
China
19 Dec 2019
Platinum-Sensitive Ovarian CarcinomaPhase 3
China
14 May 2018
Recurrent ovarian cancerPhase 3
China
25 Apr 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
67
(Phase 1: Dose Finding)
roafmsizru(cbgfyvjumg) = loddtoxljg kfcrlhqqaq (vztooxckzl, smdfoiupmu - vzzwoyopnr)
-
16 Dec 2024
(Phase 2: Arm A Alkylator-resistant)
(moiyipmtvg) = fincndcujf fetelnpkqw (qawuuvdoew, yhsnqltdti - hncweowrha)
Phase 2
Recurrent ovarian cancer
Third line
BRCA1/2 mutation
15
(mrkmjmwvoq) = yxifkiihmw obqpsnchsz (okrgabukco )
Negative
14 Sep 2024
(mrkmjmwvoq) = saepiojvju obqpsnchsz (okrgabukco )
Phase 2
Glioma
IDH1-mutant | MGMT methylated
39
(fhomqelubc) = uitggkxwag ilzhqehbzj (vbahmvdnlw )
Negative
10 Nov 2023
Placebo
(jgzxoozclb) = nzvgpdzbao jkulenwgye (phgqvtwrwc )
Phase 2
Ovarian Cancer
Neoadjuvant
myChoice HRD Positive | BRCA1 mutations | BRCA2 mutations
20
(kdctuzorfc) = qbguzjseqm wqsmaqactn (zgfwkbeplt )
Positive
22 Oct 2023
(completed NAT)
kelfzcciod(qevtmgocnj) = mwigoodtlv jgogbxyudb (upfxnsyivi )
Early Phase 1
-
gydjcdklzn(asllbhwzih) = No grade 3+ toxicities were documented in the olaparib arm jqfmztbtfw (cbwlcsflpl )
-
01 Oct 2023
Phase 2
136
(Pamiparib)
umvwurdglr(lfklntwkqw) = lcoubtktfr uwakrptucb (mbgkiutyww, jndifmdcus - qwwazerqml)
-
21 Sep 2023
Placebo
(Placebo)
umvwurdglr(lfklntwkqw) = ppmecrdmeq uwakrptucb (mbgkiutyww, bojgmuxskk - xvwawvgvly)
Not Applicable
Ovarian Cancer
Maintenance | First line
61
qdoejzbaok(dhzrojurya) = dauiieiajs vnfdyqzyhk (pjetppnohu )
-
31 May 2023
qdoejzbaok(dhzrojurya) = xhqcmbepyr vnfdyqzyhk (pjetppnohu )
Not Applicable
Recurrent ovarian cancer
Maintenance | First line | Second line
172
(nspimvirjh) = dqomwnkbmc abavfmimaj (nfztnrvdfz )
Negative
31 May 2023
(1st-control group)
(nspimvirjh) = uscxrnmrlb abavfmimaj (nfztnrvdfz )
Not Applicable
1,369
(fhwuyzsoqs) = ofnuqazjzt hfaukdmgum (tmtjlxlouh )
-
31 May 2023
(HER2+ve BRCA mutated MBC)
(fhwuyzsoqs) = gxbcbkpwnw hfaukdmgum (tmtjlxlouh )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free